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GeBACKGROUND The use of transcatheter mitral valve repair (TMVR) has gained widespread acceptance in Europe, but
data on immediate success, safety, and long-term echocardiographic follow-up in real-world patients are still limited.
OBJECTIVES The aim of this multinational registry is to present a real-world overview of TMVR use in Europe.
METHODS The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective, independent, consecutive
collection of individual patient data.
RESULTS A total of 628 patients (mean age 74.2  9.7 years, 63.1% men) underwent TMVR between January 2011 and
December 2012 in 25 centers in 8 European countries. The prevalent pathogenesis was functional mitral regurgitation
(FMR) (n ¼ 452 [72.0%]). The majority of patients (85.5%) were highly symptomatic (New York Heart Association
functional class III or higher), with a high logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation)
(20.4  16.7%). Acute procedural success was high (95.4%) and similar in FMR and degenerative mitral regurgitation
(p ¼ 0.662). One clip was implanted in 61.4% of patients. In-hospital mortality was low (2.9%), without signiﬁcant
differences between groups. The estimated 1-year mortality was 15.3%, which was similar for FMR and degenerative
mitral regurgitation. The estimated 1-year rate of rehospitalization because of heart failure was 22.8%, signiﬁcantly
higher in the FMR group (25.8% vs. 12.0%, p[log-rank] ¼ 0.009). Paired echocardiographic data from the 1-year
follow-up, available for 368 consecutive patients in 15 centers, showed a persistent reduction in the degree of mitral
regurgitation at 1 year (6.0% of patients with severe mitral regurgitation).
CONCLUSIONS This independent, contemporary registry shows that TMVR is associated with high immediate
success, low complication rates, and sustained 1-year reduction of the severity of mitral regurgitation and improvement
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876M itral valve surgery is the treat-ment of choice for patients withsevere mitral regurgitation (MR)
who develop symptoms and/or demonstrate
worsening of left ventricular (LV) function
(1) (Figure 1); however, a signiﬁcant number
of patients cannot undergo mitral valve
(MV) surgery because of their prohibitive sur-
gical risk (2). Previous reports suggest that
this may account for approximately one-halfSEE PAGE 885of the patients being considered for mitral
surgery (3,4). The MitraClip system (Abbott
Vascular, Santa Clara, California), conceived
for transcatheter mitral valve repair (TMVR),
received regulatory approval in Europe in
2008 and has already gained widespread clin-
ical application. The system is based on the
edge-to-edge repair concept, a technique
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effective than surgery in reducing MR but induced
fewer perioperative adverse events and yielded
similar improvement in functional status. These re-
sults were maintained at 4 years in patients with a
successful initial repair (6). Subsequent observational
studies with wider clinical and echocardiographic in-
clusion criteria have conﬁrmed the beneﬁt of TMVR
in patients with severe LV dysfunction, patients not
responding to cardiac resynchronization therapy,
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877this report is to present a real-world overview of de-
vice use focusing on patient characteristics, clinical
indications, techniques, in-hospital outcomes, and
1-year outcomes.FIGURE 1 Pathogenetic Process of Degenerative and Functional Mitral Regurgitation
(A) Degenerative mitral regurgitation is a consequence of a spectrum of conditions in
which morphological changes in the connective tissue of the mitral valve cause structural
lesions (such as chordal elongation, leaﬂet tissue expansion) that prevent normal function
of the mitral apparatus, leading to leaﬂet prolapse. (B) Functional mitral regurgitation is a
consequence of left ventricular remodeling after myocardial injury (dilated cardiomyo-
pathy, ischemic left ventricular insufﬁciency, and so on), with enlargement of the left
ventricular chamber and mitral annulus, apical and lateral migration of the papillary
muscles, leaﬂet tethering, and reduced closing forces. These processes lead to incomplete
coaptation of the leaﬂets and variable degrees of mitral regurgitation that can ﬂuctuate
dynamically as a function of volume status, afterload, heart rhythm, and residual ischemia.
The leaﬂets themselves are normal, and the disease primarily affects the myocardium
rather than the valve itself. Ao ¼ ascending aorta; LA ¼ left atrium; LV ¼ left ventricle.METHODS
Twenty-ﬁve centers in 8 European countries
contributed to this registry (Online Appendix). They
prospectively entered data on consecutive patients
from January 2011 (or from the time of ethics com-
mittee approval) to December 2012 via a dedicated
Internet-based Case Record Form hosted and
managed at the European Society of Cardiology Heart
House. The EuroObservational Research Programme
team generated queries to clean the database and
validate entries. A total of 155 of 628 cases (24.6%)
were audited on site. This pilot registry received no
direct commercial sponsorship from the device
manufacturer, which produced the only CE-marked
commercially available device for transcatheter MV
repair during the study period.
At participating centers, all consecutive patients
receiving transcatheter mitral edge-to-edge repair
with TMVR were prospectively entered into the regis-
try. The only exclusion criterion was refusal to sign
the agreement to enter data, which was approved by
the ethics committees of the participating centers.
The MitraClip system is a 4-mm-wide, polyester-
covered, cobalt-chromium, V-shaped device with
2 movable arms. With the patient under general
anesthesia and with the use of ﬂuoroscopic and
transesophageal echocardiographic guidance (17),
transseptal puncture is performed, which enables the
advancement of a 24-F torqueable sheath from the
femoral vein into the left atrium. The MitraClip
catheter is then advanced across the MV into the LV
with the clip arms opened with a perpendicular
orientation to the coaptation line. When the opened
arms are withdrawn, the leaﬂets fall into the clip and
are secured between the arms and the grippers,
which creates a double-oriﬁce valve. If an acceptable
reduction in MR is achieved without a critical
increase in transmitral gradient and adequate sta-
bility is demonstrated, the clip is detached from the
delivery system. In patients with broad regurgitant
jets, the use of a second clip is now considered a
common technique to improve results (18).
ENDPOINTS AND DEFINITIONS. Procedural success
was deﬁned as a reduction in the degree of MR
to equal to or less than moderate (#2þ) without
complications (5). Clinical and echocardiographic
follow-up was performed at discharge and at 1 and12 months after implantation. For the echocardio-
graphic analysis substudy, we selected centers
(15 of 25) with a follow-up rate of at least 90% (n¼ 383),
because we expected positive or negative bias to
modify the characteristics of the patients assessed in
the remaining centers. Only patients with paired
echocardiographic observations during follow-up
were included in the analysis (n ¼ 368 [61%]).
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD or as median and interquartile
range, as appropriate. Between-group comparisons
were made with a nonparametric test (Kruskal-Wallis
test). Categorical variables are reported as percent-
ages. Between-group comparisons were made with a
chi-square test (Fisher exact test if the expected cell
count was <5). Univariate analysis was applied to
both continuous and categorical variables. Multivar-
iate logistic regression analysis was used to identify
the variables independently associated with the
combined endpoint of death or readmission because
of heart failure at 1 year. We included all variables
correlated with the combined endpoint at p < 0.1 or
expected from previous studies to inﬂuence outcome.
Because we used the EuroSCORE (European System
for Cardiac Operative Risk Evaluation) as an overall
TABLE 1 Baseline Clinical Characteristics
Overall
(n ¼ 628)
Mixed/
Other
(n ¼ 17)
Functional MR
(n ¼ 452)
Degenerative MR
(n ¼ 143) p Value*
Age, yrs 74.2  9.7 78.0  8.4 72.8  9.8 78.3  8.5 <0.001
Male 63.1 41.2 67.7 52.5 <0.001
Diabetes mellitus 27.9 11.8 33.1 12.6 <0.001
Hypertension 75.9 88.2 77.6 69.0 0.038
COPD 19.3 11.8 19.8 20.3 0.905
Previous stroke 14.4 17.7 12.8 18.2 0.109
Signiﬁcant CAD 30.9 29.4 31.9 25.9 0.659
Previous MI 31.2 25.5 37.6 13.3 <0.001
Previous PCI† 15.5 11.8 16.4 14.1 0.515
Previous CABG 32.3 35.3 34.9 21.7 <0.003
Previous valve
surgery
10.4 5.9 9.7 11.9 0.459
NYHA functional
class
0.004
I 1.6 0.0 1.1 3.5
II 12.9 23.5 10.4 19.6
III 68.7 52.9 70.3 63.6
IV 16.8 23.5 18.2 13.3
AFib/ﬂutter 31.7 18.8 27.2 50.0 <0.001
LVEF <30% 32.8 12.5 42.0 2.8 <0.001
Baseline SCr,
mmol/l
132.0  80.5 115.7  37.2 137.7  88.0 112.6  45.8 0.002
CKD 30.5 17.7 32.8 24.1 0.051
Hemodialysis 9.2 0.0 9.3 10.5 0.634
EuroSCORE 20.4  16.7 15.5  11.2 21.9  17.6 16.3  13.7 0.003
Values are mean  SD or %. *p Value for comparisons between functional and degenerative mitral regurgitation.
†Within 3 months.
AFib ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease; CKD ¼
chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System for
Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; MR ¼
mitral regurgitation; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; SCr ¼
serum creatinine.
UK
Switzerland
Sweden
Italy
Germany
Denmark
Belgium
17.1
37.5
59.2
14.7
44.4
16.9
81.6
23.5
76.1
18.9
72.1
28.6
96.2
EuroSCORE
Functional MR (%)
FIGURE 2 Geographic Variation of Mean Logistic EuroSCORE
and Prevalence of Functional MR Pathogenesis
There is marked variation between countries with regard to
the type of mitral regurgitation (MR) treated and the surgical
predicted risk. EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation.
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878estimation for the risk of patients, we excluded all the
components used for its calculation to avoid collin-
earity. MR severity and New York Heart Association
(NYHA) functional class were compared between
different time points (baseline, discharge, 1 month,
and 12 months) by use of the Bowker test. Changes in
echocardiographic measurements between different
time points (baseline, discharge, and 12 months) were
analyzed with paired Student t tests. Survival rates
up to 12 months were presented as Kaplan-Meier
curves. Differences were considered statistically sig-
niﬁcant at p values <0.05.
All analyses were performed with SAS statistical
software version 9.2 (SAS Institute, Inc., Cary, North
Carolina). The multivariate logistic regression anal-
ysis was performed with program R (Vienna Univer-
sity of Economics and Business Administration,
Vienna, Austria) and the package Hmisc (Vanderbilt
University, Nashville, Tennessee).RESULTS
BASELINE CHARACTERISTICS. Between January
2011 and December 2012, 628 patients (mean age
74.2  9.7 years) were entered into the database.
Baseline characteristics for the entire population are
displayed in Table 1. The prevalent pathogenesis was
functional mitral regurgitation (FMR) (n ¼ 452
[72.0%]). In the overall population, men predomi-
nated (63.1%), but patients with degenerative MR
(DMR) showed an almost equal distribution of men
and women (52% vs. 48%). The vast majority of pa-
tients were highly symptomatic (NYHA functional
class >III, 85.5%) and at high surgical risk (logistic
EuroSCORE 20.4  16.7%). Mean logistic EuroSCORE
and prevalence of FMR according to country are dis-
played in Figure 2. There was a marked heterogeneity
among countries with regard to the pathogenesis of
MR and the surgical risk of patients selected for
TMVR.
PROCEDURAL AND IN-HOSPITALOUTCOMES. Procedural
variables and in-hospital outcomes are displayed in
Table 2. Acute procedural success was high (95.4%)
and equivalent between groups (p ¼ 0.304). One clip
was implanted in the majority of cases (61.4%), 2 clips
were implanted in 35.1% of cases, and very few
patients received 3 or more clips (2.4%). Patients with
DMR tended to receive a greater number of clips than
those with FMR ($2 clips implanted in 62 patients
with DMR [44.3%] vs. 162 patients with FMR [36.5%],
p ¼ 0.098). Overall, in-hospital mortality was 2.9%
TABLE 2 Procedural/In-Hospital Clinical Outcomes
Overall*
(n ¼ 628)
Functional
MR (n ¼ 452)
Degenerative
MR (n ¼ 143) p Value†
Death 2.9 2.0 4.9 0.075
Tamponade 1.1 0.7 1.8 0.298
Stroke 0.2 0.0 0.7 0.241
Severe bleeding 1.1 0.9 2.1 0.368
Transfusion 10.1 9.7 12.4 0.406
Vascular complication
requiring intervention
0.7 1.0 0.0 0.581
New-onset atrial
ﬁbrillation
11.7 12.6 10.2 0.599
Acute procedural
success
95.4 95.8 93.7 0.304
Clip embolization 0.7 0.5 0.9 0.521
Inability to reduce
MR
3.5 3.0 4.4 0.387
Implant $2 clips 37.5 36.5 44.3 0.098
Procedure duration, min 138.3  67.9 137.2  68.2 132.1  65.6 0.463
Median hospital
stay (IQR), d
5 (3–7) 5 (4–7) 5 (3–7) 0.348
Values are % or mean  SD, unless otherwise noted. *Includes the 17 mixed/other patients.
†p Value for comparisons between functional and degenerative mitral regurgitation.
IQR ¼ interquartile range; MR ¼ mitral regurgitation.
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879(18 of 628 patients) and ranged between 4.9% (7 of
143 patients) in the DMR group and 2.0% (9 of
452 patients) in the FMR group (p ¼ 0.075).
Two patients died in the group with mixed/unknown
pathogenesis. Cardiac tamponade and stroke were
infrequent (1.1% and 0.2%, respectively). Vascular
damage and profuse bleeding that required multiple
transfusions were rare (1.1% and 0.7%, respectively).
The need for transfusion of at least 1 U of blood was
seen in 10.1% of patients.
ECHOCARDIOGRAPHIC DATA AT ADMISSION AND
DISCHARGE. Baseline and post-procedural paired
echocardiographic data are displayed in Table 3. At
baseline, patients with FMR had larger LV volumes
(p < 0.001) and a signiﬁcantly lower LV ejection
fraction (LVEF; p < 0.001). By contrast, patients with
DMR presented with more severe MR on both semi-
quantitative and quantitative echocardiographic pa-
rameters. They also had signiﬁcantly higher systolic
pulmonary pressure values (p < 0.001). Echocardio-
grams obtained before discharge showed a marked
reduction in MR less than or equal to moderate in
98.2% of patients, with equivalence between groups
(p ¼ 0.910). Overall, a signiﬁcant reduction in atrial
volumes (mean change in left atrial volume 10.4 ml,
p ¼ 0.004) and systolic pulmonary artery pressure
(SPAP) (mean DSPAP 5.8 mm Hg, p < 0.001) was
observed at discharge. LVEF showed a small but sig-
niﬁcant decrease after repair (mean DLVEF 1.0%,
p ¼ 0.020), especially in the DMR group (DLVEF 4.4%,
p < 0.001). In both FMR and DMR patients, signiﬁcantTABLE 3 Echocardiographic Variables Before and After TMVR
Overall (n ¼ 368)
Pre-Clip Post-Clip D p Value
LVEDV, ml 159.4  86.1 154.8  86.3 4.6 0.119
LVESV, ml 103.0  69.0 102.4  74.6 0.6 0.797 1
LA volume, ml 120.8  66.3 110.4  58.1 10.4 0.004 1
LVEF, % 42.6  15.9 41.6  15.0 1.0 0.020
Degree of
MR, %
<0.001
None/mild 0.7 72.8
Moderate 13.2 25.4
Severe 86.1 1.8
MR quantiﬁcation
EROA, cm2 0.43  0.16 — —
VC, mm 7.5  2.7 — —
RV, ml 53.8  27.6 — —
Mean TMG, mm Hg 2.0  1.2 3.4  2.0 1.4 <0.001
SPAP, mm Hg 46.0  14.5 40.2  11.7 5.8 <0.001
Values are mean  SD or %.
DMR ¼ degenerative mitral regurgitation; EROA ¼ effective regurgitant oriﬁce area; F
ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; MR ¼ mitra
gradient; TMVR ¼ transcatheter mitral valve repair; VC ¼ vena contracta.changes were demonstrated in atrial volume and
pulmonary pressure. There was a signiﬁcant increase
in the mean transmitral pressure gradient for both
types of MR, but without signiﬁcant differences
between groups.
FOLLOW-UP RESULTS: CLINICAL OUTCOMES. Twelve-
month clinical follow-up was obtained in 552 patientsFMR (n ¼ 264) DMR (n ¼ 85)
Pre-Clip Post-Clip D p Value Pre-Clip Post-Clip D p Value
171.1  90.2 167.0  90.8 4.1 0.212 118.9  57.9 113.1  54.3 5.8 0.265
16.3  71.3 114.8  78.4 1.5 0.634 54.0  32.4 56.5  33.4 2.5 0.313
22.5  59.7 113.4  57.9 9.1 0.029 114.1  85.4 99.3  63.2 14.8 0.040
37.1  13.6 37.0  13.5 0.1 0.792 59.9  9.3 55.5  9.6 4.4 <0.001
<0.001 <0.001
1.0 71.9 0 72.1
14.3 26.1 9.8 26.2
84.7 2.0 90.2 1.6
0.42  0.15 — — 0.46  0.18 — —
7.5  2.7 — — 7.6  2.9 — —
51.1  27.7 — — 62.7  21.3 — —
1.9  1.3 3.4  2.1 1.5 <0.001 2.3  1.3 3.6  1.6 1.3 0.003
44.2  13.2 39.2  11.2 5 <0.001 53.5  16.9 43.4  12.2 10.2 0.001
MR ¼ functional mitral regurgitation; LA ¼ left atrial; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left
l regurgitation; RV ¼ regurgitant volume; SPAP ¼ systolic pulmonary artery pressure; TMG ¼ transmitral pressure
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CENTRAL ILLUSTRATION Kaplan-Meier Analysis of Survival Free From Death,
Rehospitalization Due to Heart Failure, and Composite of Death and Rehospitali-
zation, Comparing Degenerative Versus Functional Mitral Regurgitation
(A) Death, (B) rehospitalization due to heart failure, (C) composite of death and reho-
spitalization. We observed a signiﬁcant difference between the 2 types of mitral regur-
gitation with regard to readmission because of heart failure; however, no differences
between groups with regard to death or the composite endpoint were noted.
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880(88.0%). Median follow-up duration was 346 days
(interquartile range: 211–385 days). The estimated
1-year mortality was 15.3%, without signiﬁcant dif-
ferences between groups (FMR 15.0% vs. DMR 16.2%,
p[log-rank] ¼ 0.650) (Central Illustration A). The
overall Kaplan-Meier probability of survival at 1 year
was 84.7% (SD 1.7%). The estimated 1-year rate of
rehospitalization because of heart failure was 22.8%
and was signiﬁcantly higher in the FMR group than
the DMR group (25.8% vs. 12%, p[log-rank] ¼ 0.009)
(Central Illustration B). Conversely, the probability of
being free from readmission was 77.2% (SD 2.2%).
At 1 year, the estimated rate of survival free from
death or readmission because of heart failure was
69.0% (SD 2.3%). The Central Illustration C compares
the survival curves of FMR and DMR in terms of death
and the composite endpoint of death plus rehospi-
talization (p[log rank] ¼ 0.103).
The prevalence of different NYHA functional clas-
ses during follow-up is shown in Figure 3. At 1 month,
both FMR and DMR patients exhibited an improve-
ment, with 74.9% (203 of 271 patients) of the former
and 76.5% (52 of 68 patients) of the latter showing
improvement. This effect persisted over 1 year, with
most patients in NYHA functional class II or lower.
Multivariate analysis showed that EuroSCORE
(odds ratio [OR]: 1.44; 95% conﬁdence interval [CI]:
1.11 to 1.86; p ¼ 0.006), LVEF <30% (OR: 2.69; 95% CI:
1.64 to 4.42; p < 0.001), and successful clip deploy-
ment (OR: 0.12; 95% CI: 0.03 to 0.53; p ¼ 0.005) were
independently associated with the composite
endpoint at 1 year.
Reintervention at 1 year was observed in 17
patients (3.8%) in the overall population, consisting
of an additional MitraClip implantation in 13 patients
(2.9% of cases), surgical MV repair in 3 (0.7%), and
MV replacement in 1 (0.2%). No signiﬁcant differ-
ences were observed between groups in terms of
reintervention.
ECHOCARDIOGRAPHIC FOLLOW-UP. MR reduction
at hospital discharge and 1 year is shown in Figure 4. At
discharge, no signiﬁcant differences were observed
between groups, with lower degrees of MR observed in
the FMR group. At 1 year, the rate of recurrence of se-
vere MR in the DMR group was higher, albeit not
signiﬁcantly (6.6% vs. 5.9%, p ¼ 0.965).
At 1 year (Figure 5), we observed a slight, nonsig-
niﬁcant reduction in LV end-diastolic volume in pa-
tients with DMR but no change in the FMR group. The
overall cohort, especially DMR patients, showed a
decrease in LVEF (D1.4% at 1 year compared with pre-
clip, p ¼ 0.033). Patients with FMR experienced a
nonsigniﬁcant trend to an improvement in LVEF. Left
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FIGURE 3 NYHA Functional Class at Baseline and at 1-Month and 1-Year Follow-Up
We observed a relevant improvement in New York Heart Association (NYHA) functional
class in the overall cohort and for both types of mitral regurgitation (MR). At 1 year,
patients with functional MR were more frequently in NYHA functional class III or IV than
patients with degenerative MR. FU ¼ follow-up.
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FIGURE 4 Severity of Mitral Regurgitation at Baseline and Follow-Up (Discharge and
1-Year Follow-Up) After TMVR
A signiﬁcant reduction in the degree of mitral regurgitation was noted, with no difference
between functional and degenerative mitral regurgitation. This reduction persisted at
1 year. FU ¼ follow-up; TMVR ¼ transcatheter mitral valve repair.
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881atrial volumes decreased signiﬁcantly, mainly in the
FMR group. SPAP showed a persistent signiﬁcant
decrease at 1 year (D5.2 mm Hg, p < 0.001). Finally,
the signiﬁcant increase in mean transmitral pressure
gradient that appeared during the in-hospital evalu-
ation was persistent at 1 year (Figure 6).
DISCUSSION
This ﬁrst report from the mitral cohort of the TCVT
European Sentinel registry presents one of the
largest independent, contemporary, real-world data
collections on the safety and efﬁcacy of MV repair
with percutaneous TMVR. Acute procedural success
was greater (>90%) than in the initial randomized
EVEREST trial but similar to the success observed in
more recent registries (10–15,19,20).
This registry also conﬁrms that patients enrolled
in contemporary clinical practice are very different
from the patients enrolled in the EVEREST clinical
trial, which was limited to surgical candidates, mainly
with preserved LV function and degenerative valve
disease. With regard to the cause of MR, 72% was
functional, at variance with EVEREST II (27% preva-
lence of FMR) but similar to recent registries (66% in
TRAMI [Transcatheter Mitral Valve Interventions],
69% in ACCESS-EU [ACCESS-Europe, A Two-Phase
Observational Study of the MitraClip System in
Europe], and 60% in EVEREST high-risk) (11,13,21). In
the present registry, there was a high prevalence
of ischemic heart disease, LV dysfunction, and
NYHA functional class III or IV (>85% of patients).
These features, together with other comorbidities and
the old age of the patients, especially in the DMR
group, translated into a high logistic EuroSCORE,
with an average >20%. The widespread use of TMVR
for patients with heart failure and secondary MR is
explained by the suboptimal results and high mor-
tality of surgical correction (22–24). In EVEREST II,
patients with advanced age, secondary FMR, and
depressed LVEF had similar results with TMVR and
surgery, compared with previous registries focused
on this high-risk group that showed promising re-
sults for both MR reduction and functional class
improvement (7–9,11,13,21,25).
It is important to stress the overall high acute
procedural success (95.4%) achieved with a techni-
cally demanding procedure, which was similar
between the FMR and DMR groups. Notably, acute
procedural success was even higher than in contem-
porary registries (91% in ACCESS-EU and 94% in
TRAMI) (13,21). Greater operator, imaging, and anes-
thesiology team experience is the most likely expla-
nation for the greater MR reduction with fewercomplications and a shorter procedure time than in
early reports (26). It is important to highlight that
almost 38% of patients received more than 1 clip, and
nearly half of the patients with DMR required $2
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FIGURE 5 Echocardiographic Measurement of Left Ventricular and
Left Atrial Volumes at Baseline, Discharge, and 1-Year Follow-Up After TMVR
(Paired Data From 368 Patients)
In the overall cohort, a nonsigniﬁcant reduction in left ventricular end-diastolic volume
(LVEDV) was observed, with a signiﬁcant reduction in left atrial volume (LA). In functional
mitral regurgitation, left ventricular volumes remained stable during follow-up, although a
signiﬁcant reduction in LA was noted. In degenerative mitral regurgitation, the most
relevant ﬁnding was a reduction in LVEDV over time (nonsigniﬁcant). LVESV ¼ left ven-
tricular end-systolic volume; TMVR ¼ transcatheter mitral valve repair.
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882clips. The EVEREST subanalysis (27) showed that
patients with more severe MR (measured by higher
regurgitant volumes) were more likely to receive
more than 1 clip to achieve an optimal MR reduction,Overall Functional Degenerative
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FIGURE 6 Echocardiographic Measurement of Transmitral Pressure
and 1-Year Follow-Up
Signiﬁcant and persistent reductions in systolic pulmonary artery pressu
transmitral pressure gradient (TMG) (mm Hg) increased signiﬁcantly, alt
ventricular ejection fraction (%).whereas previous data from Franzen et al. (8) showed
that in 80% of patients with end-stage heart failure,
MR can be successfully treated with a single clip.
Successful reduction of MR is of paramount impor-
tance to maximize the clinical beneﬁt of the proce-
dure (19,28). With proper patient selection, the
implantation of $2 clips is not associated with higher
gradients or lower MV area at follow-up than the use
of just 1 clip (29).
Numerically, in-hospital mortality was lower than
in previous registries in high-risk populations
(10,11,13,19), with higher rates observed in the DMR
than in the FMR group. This ﬁnding may be explained
by the fact that although patients with DMR had
lower logistic EuroSCOREs and therefore expected
lower rates of in-hospital adverse events, they were
signiﬁcantly older and had more severe MR and pul-
monary hypertension, together with other adverse
factors that were not taken into account in the risk
score calculation.
The registry conﬁrmed that TMVR confers sus-
tained clinical beneﬁt, with persistent severe MR in
1.8% of cases immediately post-procedure and 6% at 1
year, a long-term improvement already observed in
other real-world registries (e.g., 80% MR #2þ in
ACCESS-EU at 1 year) (12,13,21). Patients with DMR, in
whom regurgitant volume plays the key role in the
pathophysiology of LV remodeling, showed a
considerable although not signiﬁcant decrease in LV
end-diastolic volume. Conversely, in patients with
FMR, LV volumes at 1 year presented an increase from
the post-procedure values, likely caused by theOverall Functional Degenerative
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re (SPAP) were observed. After transcatheter mitral valve repair,
hough no cases of severe mitral stenosis were reported. LVEF ¼ left
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Experience in
Europe with percutaneous TMVR suggests efﬁcacy in reducing
the severity of primary mitral regurgitation with a relatively low
complication rate and persistent improvement in functional class
in most patients.
TRANSLATIONAL OUTLOOK: The results of randomized
trials should provide more information about the value of TMVR
as a palliative adjunctive treatment of heart failure patients with
severe primary mitral regurgitation refractory to mediation
therapy.
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883underlying myocardial disease. The correction of
mitral insufﬁciency alters just 1 of the multiple
mechanisms that lead to progressive LV dilation, and
LV volumes can remain high despite a signiﬁcant
reverse atrial remodeling after implantation of the
clip, a ﬁnding that suggests an effective correction
of the volume overload. It must be stressed as well
that patients with FMR in this trial were treated in
an advanced stage of evolution of their disease.
With earlier correction of MR, we speculate that a
favorable LV remodeling may still occur. Volumetric
reductions were more pronounced in the EVEREST
trial, which is possibly explained by the inclusion
of an older population with more advanced disease
in our registry. In addition, the different proportion
of patients with DMR and FMR may account for
the differences observed between our data and the
EVEREST analyses with regard to LV remodeling
(30,31).
NYHA functional class showed improvement dur-
ing follow-up for both FMR and DMR patients,
although at 1 year, the proportion of patients with
FMR in a more advanced functional class was higher
than in patients with DMR. The 1-year mortality rate
was comparable to the mortality reported in the most
recent registry (21), with no signiﬁcant difference in
the rate of mortality of FMR and DMR patients. The
variable with the strongest association with the
combined endpoint of death or rehospitalization for
heart failure was the inability to implant a clip and
reduce MR. This ﬁnding was addressed recently in a
report from the EVEREST investigators in a subset of
patients with DMR: The degree of residual MR after
the procedure was linked to a worse outcome, with an
increase in the rates of death and rehospitalization
because of heart failure (32). Notably, our data and
the recently published ACCESS-EU (21) show a 1-year
survival that is similar to the rate in the most
contemporary trial of surgical correction of FMR but
in patients with very high surgical risk (33).
STUDY LIMITATIONS. First, the TCVT registry is a
pilot, voluntary registry. Thus, procedural complica-
tions, adverse events, and echocardiography param-
eters are self-reported. Second, despite the extreme
simpliﬁcation of the follow-up data requested, which
excluded, for instance, drug regimen, the complete-
ness of follow-up for clinical events (88%) and
especially echocardiographic data (61%) is far from
ideal. However, the centers compliant with full
echocardiographic data entry provided nearly com-
plete entry of their consecutive 368 patients with
paired echocardiographic data, a group that is one of
the largest series in the literature and reportscomplete data in terms of serial volumes and atrio-
ventricular gradients, which are essential to under-
stand the effects of TMVR on LV remodeling and MR
reduction.
Registries do not eliminate the need for properly
randomized controlled trials with external adjudica-
tion and core laboratory analysis of data with great
subjectivity, such as, for instance, severity of mitral
insufﬁciency. Still, they offer the opportunity to un-
derstand whether trial results are applicable to real-
life settings and, conversely, help to provide the key
outcome measures to design meaningful future
controlled studies.
CONCLUSIONS
In this large contemporary registry addressing the
effect of TMVR on MR reduction, functional class
improvement, and clinical events, both FMR and
DMR exhibited an immediate reduction in the
severity of MR and improvement in functional class
that persisted at 1 year. Procedural and late mortality
was low and lower than expected in such a high-risk
cohort, without differences between FMR and DMR.
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